258 related articles for article (PubMed ID: 30762300)
1. Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer.
Wang Z; Zhang H; Zhou C; Long X; Guan R; Yang N; Zhang Y
Cancer Med; 2019 Apr; 8(4):1434-1441. PubMed ID: 30762300
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy.
Zhou S; Zuo L; He X; Pi J; Jin J; Shi Y
Thorac Cancer; 2018 Nov; 9(11):1354-1360. PubMed ID: 30152052
[TBL] [Abstract][Full Text] [Related]
3. Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study.
Pu X; Wang Q; Liu L; Chen B; Li K; Zhou Y; Sheng Z; Liu P; Tang Y; Xu L; Li J; Kong Y; Xu F; Xu Y; Wu L
Cancer Med; 2023 Apr; 12(7):7724-7733. PubMed ID: 36494905
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of continuous infusion of Rh-endostatin combined with platinum-based chemotherapy for advanced triple-negative breast cancer.
Tan A; Wang H; Nong L; Jia Y; Liu Y; Zhong W; Qin F; Wang H; Tang J; Zhou W; Lu Y; Xie W
Ann Palliat Med; 2021 Dec; 10(12):12101-12112. PubMed ID: 35016411
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer.
Fu S; Huang H; Shang K; Tu G; Zhong P; Li S; Zhu X; Peng S; Liu Y; Lu Z; Chen L
Future Oncol; 2023 Jan; 19(2):147-158. PubMed ID: 36779488
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety of rh-endostatin combined with chemotherapy versus chemotherapy alone for advanced NSCLC: a meta-analysis review].
Cao D; Ge W; Wang H; Zhang L; Zheng Y; Zhang J
Zhongguo Fei Ai Za Zhi; 2011 May; 14(5):404-13. PubMed ID: 21569645
[TBL] [Abstract][Full Text] [Related]
8. A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer.
Lu S; Li L; Luo Y; Zhang L; Wu G; Chen Z; Huang C; Guo S; Zhang Y; Song X; Yu Y; Zhou C; Li W; Liao M; Li B; Xu L; Chen P; Hu C; Hu C
J Thorac Oncol; 2015 Jan; 10(1):206-11. PubMed ID: 25654728
[TBL] [Abstract][Full Text] [Related]
9. Comparison of endostatin combined with PT-DC versus bevacizumab combined with PT-DC in the first-line treatment of advanced lung adenocarcinoma: a retrospective propensity score-matched cohort study.
Chen X; Nie J; Dai L; Hu W; Zhang J; Han J; Ma X; Tian G; Han S; Wu D; Wang Y; Long J; Zhang Z; Fang J
Ann Palliat Med; 2021 Jul; 10(7):7847-7856. PubMed ID: 34353072
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer.
Zhao X; Mei K; Cai X; Chen J; Yu J; Zhou C; Li Q
Invest New Drugs; 2012 Jun; 30(3):1144-9. PubMed ID: 21225314
[TBL] [Abstract][Full Text] [Related]
11. The Evaluation of Durative Transfusion of Endostar Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer.
Li X; Gu G; Soliman F; Sanders AJ; Wang X; Liu C
Chemotherapy; 2018; 63(4):214-219. PubMed ID: 30347389
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer.
Zhu J; Chen G; Niu K; Feng Y; Xie L; Qin S; Wang Z; Li J; Lang S; Zhuo W; Chen Z; Sun J
Future Oncol; 2022 Mar; 18(9):1077-1087. PubMed ID: 34986655
[TBL] [Abstract][Full Text] [Related]
13. Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies.
Wang B; Xu L; Li Q; Man S; Jin C; Liu L; Zhan S; Ning Y
BMC Cancer; 2020 Oct; 20(1):1021. PubMed ID: 33087103
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis.
Zhang SL; Han CB; Sun L; Huang LT; Ma JT
Radiat Oncol; 2020 Aug; 15(1):205. PubMed ID: 32831120
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of recombinant human endostatin combined with whole-brain radiation therapy in patients with brain metastases from non-small cell lung cancer.
Chen L; Tong F; Peng L; Huang Y; Yin P; Feng Y; Cheng S; Wang J; Dong X
Radiother Oncol; 2022 Sep; 174():44-51. PubMed ID: 35788355
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer.
Han B; Xiu Q; Wang H; Shen J; Gu A; Luo Y; Bai C; Guo S; Liu W; Zhuang Z; Zhang Y; Zhao Y; Jiang L; Zhou J; Jin X
J Thorac Oncol; 2011 Jun; 6(6):1104-9. PubMed ID: 21532504
[TBL] [Abstract][Full Text] [Related]
17. Endostatin combined with platinum-based chemo-radiotherapy for advanced non-small cell lung cancer.
Jiang X; Guan W; Li M; Liang W; Qing Y; Dai N; Zhang S; Deng Y; Meng H; Yang Y; Zhong Z
Cell Biochem Biophys; 2015 Mar; 71(2):571-7. PubMed ID: 25209742
[TBL] [Abstract][Full Text] [Related]
18. Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment.
Zhou J; Zheng J; Zhang X; Zhao J; Zhu Y; Shen Q; Wang Y; Sun K; Zhang Z; Pan Z; Shen Y; Zhou J
BMC Cancer; 2018 Jan; 18(1):10. PubMed ID: 29298713
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of endostatin in combination with chemotherapy in small cell lung cancer: a phase 2 single-arm multicenter open-label trial.
Zhao Y; Zhang X; Jin C; Yu X; Zhang M; Cao Y; Li Y; Wang A; Shan X; Zhang J; Wang J; Yin L; Tan X; Liu J
Ann Palliat Med; 2021 Mar; 10(3):3277-3285. PubMed ID: 33849112
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of circulating endothelial cells for efficacy of chemotherapy with Rh-endostatin in non-small cell lung cancer.
Liu ZJ; Wang J; Wei XY; Chen P; Wang LC; Lin L; Sun BC; Li K
J Cancer Res Clin Oncol; 2012 Jun; 138(6):927-37. PubMed ID: 22331237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
